title: High-dose therapy with hematopoietic stem cell rescue in patients with poor prognosis Ewing family tumors.
abstract: The purpose of the study was to evaluate the feasibility and safety of two cycles of high-dose chemotherapy (HDT) followed by autologous hematopoietic SCT (HSCT) in patients with poor prognosis Ewing family of tumors (EFT). Twenty patients with primary metastatic bulky disease or recurrent EFT were enrolled to a treatment protocol with two cycles of HDT and HSCT. Patients tolerated well the first (n=20) and second (n=13) cycles, with limited and predictable toxicities. Only one (5%) TRM occurred during the second cycle. Myeloid engraftment occurred at the median of 11 days after both cycles. At 3 years, the overall and EFS were 45% (confidence interval; CI 0.22, 0.69) and 47% (CI 0.25, 0.70), respectively, for the entire group and 58% (CI 0.30, 0.86) for patients who completed two cycles. Dose intensification with two cycles of HDT and HSCT is feasible and safe, with low and acceptable treatment-related morbidity and mortality. Adding a second course of therapy does not impair engraftment. However, only 65% of the patients were able to proceed to the second cycle. Further studies are required to define the optimal mode of delivery of HDT and HSCT in treatment of advanced EFT.
authors.affiliation: Department of Pediatric Hematopoietic Stem Cell Transplantation, City of Hope National Medical Center, Duarte, CA 91010-3000, USA. jrosenthal@coh.org
authors.forename: J
authors.initials: J
authors.lastname: Rosenthal
authors.forename: E
authors.initials: E
authors.lastname: Bolotin
authors.forename: M
authors.initials: M
authors.lastname: Shakhnovits
authors.forename: A
authors.initials: A
authors.lastname: Pawlowska
authors.forename: P
authors.initials: P
authors.lastname: Falk
authors.forename: D
authors.initials: D
authors.lastname: Qian
authors.forename: C
authors.initials: C
authors.lastname: Oliver
authors.forename: J
authors.initials: J
authors.lastname: Sato
authors.forename: J
authors.initials: J
authors.lastname: Miser
authors.forename: S
authors.initials: S
authors.lastname: Forman
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001859:Bone Neoplasms / Q000401:mortality / Q000628:therapy*; D002648:Child; D018572:Disease-Free Survival; D005260:Female; D006085:Graft Survival; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D012512:Sarcoma, Ewing / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate; D013997:Time Factors; D014182:Transplantation, Autologous